Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Preventive Medicine
- Trends and geographic patterns in drug and synthetic opioid overdose deaths – United States, 2013-2019.MMWR Morb Mortal Wkly Rep. 2021; 70: 202-207https://doi.org/10.15585/mmwr.mm7006a4
- COVID-19 pandemic impact on patients, families and individuals in recovery from substance use disorders.Addiction Policy Forum, Bethesda, MDMay 2020PublishedAccessed March 1, 2021)
- Drug overdose deaths head toward record number in 2020, CDC warns.JAMA Health Forum. 2020; 1e201318https://doi.org/10.1001/jamahealthforum.2020.1318
Medication assisted treatment. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/medication-assisted-treatment. Updated March 1, 2022. Accessed April 5, 2022.
- Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families.Substance Abuse and Mental Health Services Administration, 2021UpdatedAccessed April 5, 2022)
- Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions.JAMA. 2019; 321: 1407-1408https://doi.org/10.1001/jama.2019.0834
- Policy pathways to address provider workforce barriers to buprenorphine treatment.Am J Prev Med. 2018; 54 (suppl 3): S230-S242https://doi.org/10.1016/j.amepre.2017.12.022
- The new mobile methadone rules and what they mean for treatment access.HealthAffairs, Bethesda, MD2021. Published August 4. Accessed March 4, 2022)
- Trends in buprenorphine treatment in the United States, 2009-2018.JAMA. 2020; 323: 276-277https://doi.org/10.1001/jama.2019.18913
- Buprenorphine treatment divide by race/ethnicity and payment.JAMAPsychiatry. 2019; 76: 979-981https://doi.org/10.1001/jamapsychiatry.2019.0876
- Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19.J Subst Abuse Treat. 2021; 122108214https://doi.org/10.1016/j.jsat.2020.108214
- Racial inequity in medication treatment for opioid use disorder: exploring potential facilitators and barriers to use.Drug Alcohol Depend. 2021; 227108927https://doi.org/10.1016/j.drugalcdep.2021.108927
- Racial disparities in use of non-emergency outpatient care by Medicaid-eligible adults after release from prison: Wisconsin, 2015–2017.J Subst Abuse Treat. 2021; 126108484https://doi.org/10.1016/j.jsat.2021.108484
- The opioid epidemic and Medicaid's role in facilitating access to treatment.Kaiser Family Foundation, San Francisco, CA2019https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment/(Published May 24Accessed April 14, 2021)
Transformed Medicaid Statistical Information System (T-MSIS). Medicaid.gov.https://www.medicaid.gov/medicaid/data-systems/macbis/transformed-medicaid-statistical-information-system-t-msis/index.html. Updated April 1, 2021. Accessed April 14, 2021
- Fewer pharmacies in Black and Hispanic/latino neighborhoods compared with White or diverse neighborhoods, 2007-15.Health Aff (Millwood). 2021; 40: 802-811https://doi.org/10.1377/hlthaff.2020.01699
- Addressing racial and ethnic disparities in the use of medications for opioid use disorder.Health Aff (Millwood). 2021; 40: 920-927https://doi.org/10.1377/hlthaff.2020.02261
- On racism: a new standard for publishing on racial health inequities.HealthAffairs, Bethesda, MD2020https://www.healthaffairs.org/do/10.1377/forefront.20200630.939347/(Published July 2.)Date accessed: March 7, 2022
HHS. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. Filed April, 27, 2021. https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder. Accessed April 28, 2021.
- Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States.JAMA Netw Open. 2020; 3e203711https://doi.org/10.1001/jamanetworkopen.2020.3711
- Management of opioid use disorder in the USA: present status and future directions.Lancet. 2019; 393: 1760-1772https://doi.org/10.1016/S0140-6736(18)33078-2
- Methadone as social control: institutionalized stigma and the prospect of recovery.Qual Health Res. 2012; 22: 810-824https://doi.org/10.1177/1049732311432718